Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 7/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3497793 | 0.85 | POLB (0.53) | HRH3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL3496117 | 0.83 | RECQL (0.46) | POLBPDE4BEIF4A3PDE4DCHRM2 | |
| SCHEMBL3496122 | 0.81 | HDAC8 (0.49) | HDAC1HDAC2HDAC10HDAC8HDAC6 | |
| SCHEMBL3497033 | 0.80 | PDE4B (0.44) | HDAC1HDAC8HDAC6POLBPDE4B | |
| SCHEMBL3496711 | 0.79 | DRD2 (0.58) | HRH3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL3497168 | 0.79 | PDE4B (0.43) | HDAC1HDAC8HDAC6POLBPDE4B | |
| Hydrochloric Acid SCHEMBL3498566 | 0.78 | DRD2 (0.57) | HRH3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL4457997 | 0.77 | DRD2 (0.46) | HRH3POLBPDE4BEIF4A3 | |
| SCHEMBL8080727 | 0.75 | HTR6 (0.49) | HRH3HDAC1HDAC2HDAC10HDAC8 | |
| SCHEMBL6397963 | 0.74 | HRH3 (0.42) | HRH3HDAC1HDAC8HDAC6PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | claimed |
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| WO-2009012252-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | HRH3 2/4885HDAC1 1951/4885HDAC2 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.